tetano
Editor, Senior Moderator
Viral Immunol. 2016 Jul 22. [Epub ahead of print]
[h=1]Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice.[/h] Liepkalns JS[SUP]1[/SUP], Pandey A[SUP]1[/SUP], Hofstetter AR[SUP]1,[/SUP][SUP]2[/SUP], Kumar A[SUP]1[/SUP], Jones EN[SUP]1[/SUP], Cao W[SUP]1[/SUP], Liu F[SUP]1[/SUP], Levine MZ[SUP]1[/SUP], Sambhara S[SUP]1[/SUP], Gangappa S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Impairment of immune defenses can contribute to severe influenza infections. Rapamycin is an immunosuppressive drug often used to prevent transplant rejection and is currently undergoing clinical trials for treating cancers and autoimmune diseases. We investigated whether rapamycin has deleterious effects during lethal influenza viral infections. We treated mice with two concentrations of rapamycin and infected them with A/Puerto Rico/8/1934 (A/PR8), followed by a heterosubtypic A/Hong Kong/1/68 (A/HK68) challenge. Our data show similar morbidity, mortality, and lung viral titer with both rapamycin treatment doses compared to untreated controls, with a delay in morbidity onset in rapamycin high dose recipients during primary infection. Rapamycin treatment at high dose also led to increase in percent cytokine producing T cells in the spleen. However, all infected animals had similar serum antibody responses against A/PR8. Post-A/HK68 challenge, rapamycin had no impeding effect on morbidity or mortality and had similar serum antibody levels against A/PR8 and A/HK68. We conclude that rapamycin treatment does not adversely affect morbidity, mortality, or antibody production during lethal influenza infections.
PMID: 27447349 DOI: 10.1089/vim.2016.0056
[PubMed - as supplied by publisher]
[h=1]Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice.[/h] Liepkalns JS[SUP]1[/SUP], Pandey A[SUP]1[/SUP], Hofstetter AR[SUP]1,[/SUP][SUP]2[/SUP], Kumar A[SUP]1[/SUP], Jones EN[SUP]1[/SUP], Cao W[SUP]1[/SUP], Liu F[SUP]1[/SUP], Levine MZ[SUP]1[/SUP], Sambhara S[SUP]1[/SUP], Gangappa S[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Impairment of immune defenses can contribute to severe influenza infections. Rapamycin is an immunosuppressive drug often used to prevent transplant rejection and is currently undergoing clinical trials for treating cancers and autoimmune diseases. We investigated whether rapamycin has deleterious effects during lethal influenza viral infections. We treated mice with two concentrations of rapamycin and infected them with A/Puerto Rico/8/1934 (A/PR8), followed by a heterosubtypic A/Hong Kong/1/68 (A/HK68) challenge. Our data show similar morbidity, mortality, and lung viral titer with both rapamycin treatment doses compared to untreated controls, with a delay in morbidity onset in rapamycin high dose recipients during primary infection. Rapamycin treatment at high dose also led to increase in percent cytokine producing T cells in the spleen. However, all infected animals had similar serum antibody responses against A/PR8. Post-A/HK68 challenge, rapamycin had no impeding effect on morbidity or mortality and had similar serum antibody levels against A/PR8 and A/HK68. We conclude that rapamycin treatment does not adversely affect morbidity, mortality, or antibody production during lethal influenza infections.
PMID: 27447349 DOI: 10.1089/vim.2016.0056
[PubMed - as supplied by publisher]